Jonathan Cohen

Alma Bio Therapeutics is a French company that aims to restore immune resilience in patients suffering from autoimmune diseases. The private company's therapeutic approach employs the language of the immune system to improve patients' health by targeting the underlying cause of the disease. The company's treatment aims to support the immune system rather than suppressing it, restoring its natural resilience and providing improved safety and an opportunity for durable remission. Alma Bio Therapeutics has developed a breakthrough therapy that is targeted, specific, and confined to the site of disease, reinstating immune balance with no overdrive or complete suppression. The company's platform-technology is applicable to several autoimmune diseases, promising to yield a versatile pipeline. The company's lead programs are directed towards diseases of complex etiology in areas of significant unmet clinical need, with inflammatory bowel disease (IBD) as their first clinical indication. Alma Bio Therapeutics is led by a seasoned management team with extensive expertise in business development, drug development, and technology commercialization.

Bionichive Ltd. introduces Squid, a fully automated, autonomous robotic solution that combines the intelligence and flexibility of humans with the power and efficiency of robots. The company is based in Ein Habsor, Israel. The Israeli company's solution is capable of pick and put-away, floor to ceiling and retrofits onto any existing warehouse. A high-end embedded control system and smart real-time data analysis allows Bionichive’s algorithmic engine to dynamically learn problems created in one warehouse and apply resolutions to all warehouses in the network. Bionichive offers a solution based on a fleet of autonomous robots, capable of floor to ceiling pick and put-away while working alongside the labor force on existing operations.